Company registration number 03781545 (England and Wales)
SURREY NANOSYSTEMS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED
30 JUNE 2025
PAGES FOR FILING WITH REGISTRAR
One Bell Lane
Lewes
East Sussex
BN7 1JU
SURREY NANOSYSTEMS LIMITED
CONTENTS
Page
Company information
1
Balance sheet
2 - 3
Notes to the financial statements
4 - 12
SURREY NANOSYSTEMS LIMITED
COMPANY INFORMATION
- 1 -
Directors
Dr D Wong
Mr D R Evans
Ms J Loncar
Mr N Crofts
(Appointed 18 October 2025)
Ms C Twemlow
(Appointed 31 October 2025)
Secretary
Haddleton & Co Limited
Company number
03781545
Registered office
East Side Business Park
Beach Road
Newhaven
BN9 0FB
Accountants
TC Group
One Bell Lane
Lewes
East Sussex
BN7 1JU
SURREY NANOSYSTEMS LIMITED
BALANCE SHEET
AS AT
30 JUNE 2025
30 June 2025
- 2 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
161,688
168,408
Tangible assets
4
335,157
449,974
496,845
618,382
Current assets
Stocks
1,330
11,330
Debtors
5
725,042
410,550
Cash at bank and in hand
422,176
1,251,544
1,148,548
1,673,424
Creditors: amounts falling due within one year
6
(508,417)
(306,231)
Net current assets
640,131
1,367,193
Total assets less current liabilities
1,136,976
1,985,575
Creditors: amounts falling due after more than one year
7
(29,959)
(39,580)
Net assets
1,107,017
1,945,995
Capital and reserves
Called up share capital
8
1,667
1,667
Share premium account
15,792,875
15,792,875
Profit and loss reserves
(14,687,525)
(13,848,547)
Total equity
1,107,017
1,945,995
SURREY NANOSYSTEMS LIMITED
BALANCE SHEET (CONTINUED)
AS AT
30 JUNE 2025
30 June 2025
- 3 -

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the board of directors and authorised for issue on 10 December 2025 and are signed on its behalf by:
Mr N  Crofts
Director
Company Registration No. 03781545
SURREY NANOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
- 4 -
1
Accounting policies
Company information

Surrey Nanosystems Limited is a private company limited by shares incorporated in England and Wales. The registered office is East Side Business Park, Beach Road, Newhaven, BN9 0FB.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.3
Research and development expenditure

Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

 

Intangible assets acquired on business combinations are recognised separately from goodwill at the acquisition date where it is probable that the expected future economic benefits that are attributable to the asset will flow to the entity and the fair value of the asset can be measured reliably; the intangible asset arises from contractual or other legal rights; and the intangible asset is separable from the entity.

SURREY NANOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 5 -

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Software
33.3% straight line basis
Patents granted
10% straight line basis
Patents not granted
Not amortised
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Plant and machinery
20% straight line basis
Fixtures and fittings
20% straight line basis
Computer Equipment
20% straight line basis
Office equipment
20% straight line basis
Leased office equipment
20% straight line basis
Production assets
20% straight line basis

Assets in the course of construction are not depreciated.

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

1.7
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

SURREY NANOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 6 -
1.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

SURREY NANOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 7 -
1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.14
Leases

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

 

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

SURREY NANOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 8 -
1.15
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

1.16
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
29
29
SURREY NANOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
- 9 -
3
Intangible fixed assets
Software
Patents granted
Patents not granted
Total
£
£
£
£
Cost
At 1 July 2024
19,485
323,090
49,594
392,169
Additions
2,463
27,529
5,997
35,989
Transfers
-
0
-
0
(23,484)
(23,484)
At 30 June 2025
21,948
350,619
32,107
404,674
Amortisation and impairment
At 1 July 2024
19,485
204,276
-
0
223,761
Amortisation charged for the year
68
19,157
-
0
19,225
At 30 June 2025
19,553
223,433
-
0
242,986
Carrying amount
At 30 June 2025
2,395
127,186
32,107
161,688
At 30 June 2024
-
0
118,814
49,594
168,408
SURREY NANOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
- 10 -
4
Tangible fixed assets
Assets under construction
Plant and machinery
Fixtures and fittings
Computer Equipment
Office equipment
Leased office equipment
Production assets
Total
£
£
£
£
£
£
£
£
Cost
At 1 July 2024
225,138
1,161,217
433,412
107,771
14,953
375,724
833,470
3,151,685
Additions
-
0
30,197
-
0
3,973
-
0
-
0
-
34,170
At 30 June 2025
225,138
1,191,414
433,412
111,744
14,953
375,724
833,470
3,185,855
Depreciation and impairment
At 1 July 2024
89,000
1,002,514
430,973
81,230
12,925
375,724
709,345
2,701,711
Depreciation charged in the year
-
0
43,721
823
8,553
468
-
0
95,422
148,987
At 30 June 2025
89,000
1,046,235
431,796
89,783
13,393
375,724
804,767
2,850,698
Carrying amount
At 30 June 2025
136,138
145,179
1,616
21,961
1,560
-
0
28,703
335,157
At 30 June 2024
136,138
158,703
2,439
26,541
2,028
-
0
124,125
449,974
SURREY NANOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
4
Tangible fixed assets
(Continued)
- 11 -
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
166,967
243,439
Corporation tax recoverable
383,467
10,110
Other debtors
174,608
157,001
725,042
410,550
6
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
177,880
157,717
Taxation and social security
35,906
35,001
Other creditors
294,631
113,513
508,417
306,231
7
Creditors: amounts falling due after more than one year
2025
2024
£
£
Other creditors
29,959
39,580
8
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of 1p each
42,003
42,003
420
420
A Ordinary shares of 1p each
124,256
124,256
1,243
1,243
A2 Ordinary shares of 0.01p each
43,261
43,261
4
4
209,520
209,520
1,667
1,667
SURREY NANOSYSTEMS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
8
Called up share capital
(Continued)
- 12 -

Holders of all classes of shares are entitled to equal voting rights.

 

On liquidation or other return of capital event, the holders of A ordinary shares and A2 ordinary shares are entitled to a sum equal to the issue price of the shares plus £100 pro rata to their shareholding less 0.0001% of the sum payable to ordinary shareholders. Once such sum has been satisfied, the ordinary shares, A ordinary shares and A2 shares rank pari-passu for distributions.

 

In the event of a sale of the company and dependant on the level of consideration achieved ordinary shares rank behind A ordinary shares and A2 shares, whereby the holders of the A ordinary shares and A2 ordinary shares will receive their issue price back first ahead of any return to the holder of ordinary shares.

2025-06-302024-07-01falsefalsefalse10 December 2025CCH SoftwareCCH Accounts Production 2025.300No description of principal activityDr D WongMr Timothy BullockMr D R EvansMr Simon KingMs J LoncarMr N CroftsMs C TwemlowHaddleton & Co Limited037815452024-07-012025-06-3003781545bus:Director12024-07-012025-06-3003781545bus:Director32024-07-012025-06-3003781545bus:Director52024-07-012025-06-3003781545bus:Director62024-07-012025-06-3003781545bus:Director72024-07-012025-06-3003781545bus:CompanySecretary12024-07-012025-06-3003781545bus:Director22024-07-012025-06-3003781545bus:Director42024-07-012025-06-3003781545bus:RegisteredOffice2024-07-012025-06-30037815452025-06-30037815452024-06-3003781545core:ComputerSoftware2025-06-3003781545core:PatentsTrademarksLicencesConcessionsSimilar2025-06-3003781545core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2025-06-3003781545core:ComputerSoftware2024-06-3003781545core:PatentsTrademarksLicencesConcessionsSimilar2024-06-3003781545core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-06-3003781545core:ConstructionInProgressAssetsUnderConstruction2025-06-3003781545core:PlantMachinery2025-06-3003781545core:FurnitureFittings2025-06-3003781545core:ComputerEquipment2025-06-3003781545core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2025-06-3003781545core:Non-standardPPEClass2ComponentTotalPropertyPlantEquipment2025-06-3003781545core:ConstructionInProgressAssetsUnderConstruction2024-06-3003781545core:PlantMachinery2024-06-3003781545core:FurnitureFittings2024-06-3003781545core:ComputerEquipment2024-06-3003781545core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2024-06-3003781545core:Non-standardPPEClass2ComponentTotalPropertyPlantEquipment2024-06-3003781545core:CurrentFinancialInstrumentscore:WithinOneYear2025-06-3003781545core:CurrentFinancialInstrumentscore:WithinOneYear2024-06-3003781545core:Non-currentFinancialInstrumentscore:AfterOneYear2025-06-3003781545core:Non-currentFinancialInstrumentscore:AfterOneYear2024-06-3003781545core:CurrentFinancialInstruments2025-06-3003781545core:CurrentFinancialInstruments2024-06-3003781545core:ShareCapital2025-06-3003781545core:ShareCapital2024-06-3003781545core:SharePremium2025-06-3003781545core:SharePremium2024-06-3003781545core:RetainedEarningsAccumulatedLosses2025-06-3003781545core:RetainedEarningsAccumulatedLosses2024-06-3003781545core:ShareCapitalOrdinaryShareClass12025-06-3003781545core:ShareCapitalOrdinaryShareClass12024-06-3003781545core:ShareCapitalOrdinaryShareClass22025-06-3003781545core:ShareCapitalOrdinaryShareClass22024-06-3003781545core:ShareCapitalOrdinaryShareClass32025-06-3003781545core:ShareCapitalOrdinaryShareClass32024-06-3003781545core:ShareCapitalOrdinaryShares2025-06-3003781545core:ShareCapitalOrdinaryShares2024-06-3003781545core:IntangibleAssetsOtherThanGoodwill2024-07-012025-06-3003781545core:ComputerSoftware2024-07-012025-06-3003781545core:PatentsTrademarksLicencesConcessionsSimilar2024-07-012025-06-3003781545core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-07-012025-06-3003781545core:PlantMachinery2024-07-012025-06-3003781545core:FurnitureFittings2024-07-012025-06-3003781545core:ComputerEquipment2024-07-012025-06-3003781545core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2024-07-012025-06-3003781545core:Non-standardPPEClass2ComponentTotalPropertyPlantEquipment2024-07-012025-06-3003781545core:Non-standardPPEClass3ComponentTotalPropertyPlantEquipment2024-07-012025-06-3003781545core:ConstructionInProgressAssetsUnderConstruction2024-07-012025-06-30037815452023-07-012024-06-3003781545core:ComputerSoftware2024-06-3003781545core:PatentsTrademarksLicencesConcessionsSimilar2024-06-3003781545core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill2024-06-30037815452024-06-3003781545core:ComputerSoftwarecore:ExternallyAcquiredIntangibleAssets2024-07-012025-06-3003781545core:PatentsTrademarksLicencesConcessionsSimilarcore:ExternallyAcquiredIntangibleAssets2024-07-012025-06-3003781545core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwillcore:ExternallyAcquiredIntangibleAssets2024-07-012025-06-3003781545core:ExternallyAcquiredIntangibleAssets2024-07-012025-06-3003781545core:ConstructionInProgressAssetsUnderConstruction2024-06-3003781545core:PlantMachinery2024-06-3003781545core:FurnitureFittings2024-06-3003781545core:ComputerEquipment2024-06-3003781545core:Non-standardPPEClass1ComponentTotalPropertyPlantEquipment2024-06-3003781545core:Non-standardPPEClass2ComponentTotalPropertyPlantEquipment2024-06-3003781545core:Non-currentFinancialInstruments2025-06-3003781545core:Non-currentFinancialInstruments2024-06-3003781545bus:OrdinaryShareClass12024-07-012025-06-3003781545bus:OrdinaryShareClass22024-07-012025-06-3003781545bus:OrdinaryShareClass32024-07-012025-06-3003781545bus:OrdinaryShareClass12025-06-3003781545bus:OrdinaryShareClass12024-06-3003781545bus:OrdinaryShareClass22025-06-3003781545bus:OrdinaryShareClass22024-06-3003781545bus:OrdinaryShareClass32025-06-3003781545bus:OrdinaryShareClass32024-06-3003781545bus:AllOrdinaryShares2025-06-3003781545bus:AllOrdinaryShares2024-06-3003781545bus:PrivateLimitedCompanyLtd2024-07-012025-06-3003781545bus:SmallCompaniesRegimeForAccounts2024-07-012025-06-3003781545bus:FRS1022024-07-012025-06-3003781545bus:AuditExemptWithAccountantsReport2024-07-012025-06-3003781545bus:FullAccounts2024-07-012025-06-30xbrli:purexbrli:sharesiso4217:GBP